Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, Yesterday
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.

PCSK9 inhibitors safe, effective for familial hypercholesterolaemia

10 Jan 2018

A meta-analysis of 1,526 patients showed that proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors are safe and effective compared with placebo at reducing LDL-cholesterol (LDL-C) in patients with familial hypercholesterolaemia (FH). [Singh A, et al, AHA 2017, abstract QCOR06]

Researchers from Brigham and Women’s Hospital in Boston, Massachusetts, US, included patients with FH from eight trials that compared PCSK9 inhibitors with standard therapy for at least 12 weeks of follow-up.

Treatment with PCSK9 inhibitors resulted in a mean 48.06 percent reduction in LDL-C compared with placebo.

Besides LDL-C, PCSK9 inhibitors were associated with the largest percent change in non–HDL-cholesterol, followed by apolipoprotein B, total cholesterol, lipoprotein (a), and triglycerides. HDL-cholesterol and Apolipoprotein A1 showed smaller percent increases.

“PCSK9 inhibitors were safe and well tolerated, with injection site reactions being the most common adverse effect,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, Yesterday
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.